{{ $ActivityName }}
Male Female
< 5 years
5-10 years
11-20 years
>20 years
Multi-specialty hospital
Clinic/ nursing home
Government hospital/ medical college
Mixed
Tier 1 city
Tier 2 city
Tier 3 city
Rural area
Dermatophytosis
Onychomycosis
Candidiasis
Aspergillosis
Cryptococcosis
Any other
Yes
No
0-25%
26-50%
51-75%
76-100%
First-generation
Second-generation
Levocetirizine
Loratadine
Bilastine
Fexofenadine
Children
Adults
Elderly
All age groups equally
As a primary treatment
As an adjunctive treatment
Only for symptomatic relief
Itching
Redness and Inflammation
Rash
Amorolfine
Clotrimazole
Miconazole
Terbinafine
Ketoconazole
Itraconazole
Fluconazole
Griseofulvin
Often
Sometimes
Rarely
Never
Desloratadine
To reduce pruritus
To manage inflammation
To improve sleep quality
Anti-histaminics
Moisturizers/emollients
Topical Jak inhibitors (Tofacitinib)
Severity of itching
Poor quality of sleep
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Visual Analogue Scale (VAS)
Itch Severity Scale
Patient self-report
Clinical observation
Any Other
5 mg
10 mg
0-20%
21-40%
41-60%
61-80%
81-100%
Effective
Very effective
Moderately effective
Less than 1 month
more than 1 month